Trials / Terminated
TerminatedNCT00050375
Clinical Trial for Ovarian Cancer (OvaRex®)
A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex® MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 354 (planned)
- Sponsor
- Unither Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.
Detailed description
This a Phase III, double-blind, placebo-controlled, multi-center study of intravenous OvaRex® MAb-B43.13 as post-chemotherapy consolidation for epithelial carcinoma of ovarian, tubal, or peritoneal origin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oregovomab |
Timeline
- Start date
- 2002-12-01
- Completion
- 2007-12-01
- First posted
- 2002-12-06
- Last updated
- 2007-12-18
Locations
62 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00050375. Inclusion in this directory is not an endorsement.